Shots:
- C4 has entered into a new collaboration with Roche to develop degrader-antibody conjugates (DACs), combining targeted protein degradation with ADCs for cancer treatment
- Partnership will focus on two oncology programs against undisclosed targets, leveraging C4’ Torpedo platform for degrader payloads, while Roche will select & design the antibodies, conjugate them to payloads, & lead activities through preclinical & clinical development as well as commercialization
- As per the deal, C4 will receive $20M upfront for two programs, with additional payment if Roche adds a third target, plus near-term discovery milestones, over $1B in discovery, regulatory & commercial milestones, and tiered royalties on future sales
Ref: Globenewswire | Image: Roche & C4 Therapeutics | Press Release
Related News: Roche Signs an Exclusive Licensing Deal with MediLink Therapeutics for YL201
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
